Tempus AI, Inc. (TEM)
NEUTRALFundamental
41
Precio
$70.07
Capitalización Bursátil
$13.12B
Parte 1 · Cuánto vale la empresa
Resumen
Tempus sells AI-driven diagnostic tests and the data platform built on top of them. Doctors, mostly oncologists, order its genomic sequencing tests to decide which cancer drugs are likely to work for a specific patient, and the results also add to a growing library of clinical and molecular data. That data library is then licensed to pharmaceutical companies, who use it to find drug targets and design clinical trials faster than they could with their own data alone.
Cómo genera ingresos
Diagnostics revenue is billed per test, largely through insurance reimbursement, so it depends on how many tests get ordered and what payers agree to pay for each one. Data and Applications revenue comes from multi-year licensing agreements with pharmaceutical companies and from Insights, a subscription-like product giving structured access to Tempus's data library. The Diagnostics business drives most of the volume and losses today, while Data and Applications carries higher margins and is growing faster.
Ingresos por segmento
Genomic and molecular sequencing tests ordered by physicians, mainly oncologists, to guide treatment decisions for individual cancer patients.
Licensing of Tempus's clinical and molecular data library to pharmaceutical companies, plus Insights, a subscription product for structured data access.
Ventaja competitiva
Patentes y licencias · EstrechaTempus's advantage rests on a data library that grows with every test it runs, linking genomic results to real clinical outcomes in a way a newcomer cannot replicate quickly. But established diagnostics competitors have their own large data sets and physician relationships, and nothing stops a hospital system from sending samples to more than one lab.
Qué impulsa la demanda
Moderadamente cíclicoTest volume follows how many patients get diagnosed with cancer and how willing physicians and insurers are to order and pay for genomic profiling, a trend that has grown steadily rather than swung with the economy. Data licensing demand instead tracks pharmaceutical research budgets, which can be cut in a downturn even as clinical demand for testing keeps rising.
Riesgos clave
- Ongoing net losses and cash burn — Tempus has never been profitable and continues to report significant net losses and negative operating cash flow, making it dependent on external financing or faster margin improvement to keep funding growth.
- Reimbursement risk on Diagnostics tests — Insurers can decline to cover a test, pay less than the cost of running it, or change coverage policy, and Diagnostics revenue depends heavily on what payers ultimately reimburse.
- A data-driven model that rivals could replicate — The value of Tempus's data library depends on continuing to add tests and partners at scale; larger, better-capitalized competitors in genomic testing could build comparable data assets over time.
- Regulatory oversight of laboratory-developed tests — Tempus's tests operate as laboratory-developed tests under evolving regulatory frameworks; a shift toward stricter FDA oversight could raise costs or slow the launch of new tests.
Concentración de clientes
Tempus signed data-licensing agreements with more than 70 pharmaceutical partners in 2025, including large companies such as AstraZeneca and Merck; the company does not disclose what share of revenue its largest partner represents.
Los argumentos a favor
Buyers argue that Tempus is building a data asset pharmaceutical companies cannot easily replicate, that landing repeat, expanding agreements with companies like AstraZeneca and Merck shows the model works commercially, and that Diagnostics volume growth of over 100% signals a business approaching the scale needed to turn a profit.
Los argumentos en contra
Sellers fear that a company still losing money at this scale depends on continued access to capital markets, that reimbursement for genomic tests can be cut by insurers at any time, and that today's data advantage narrows as competitors with equally large patient populations build their own libraries.
Written by the editors, published on 18 de agosto de 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$1.43B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$-254M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$-239M
Patrimonio Neto Total
$491M
Pasivo Total
$1.78B
Ratio de Liquidez
3.30
Cobertura de Intereses
5.12
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$63.36
Precio Actual
$70.07
Margen de Seguridad
-10.6%
Rango de Valor Justo
$60.19 - $66.52
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-49.9%
Ratio P/B
26.08
P/FCF
-
Margen Bruto
-
ROIC
-11.3%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
-11.3%
WACC
15.7%
ROIC − WACC
-27.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (9)
- EPS shows upward trend
- Price CAGR 46.77%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Revenue Growth 5Y 46.6%
- Analyst Consensus 57% Buy
- Earnings Surprise avg 36.2%
- Net Margin Trend -17.8% vs -21.0%
Fallido (10)
- ROIC -11.3%
- P/B Ratio 26.08
- Operating Margin -19.8%
- Positive Free Cash Flow
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Unknown)
- ROE -54.7%
- Share Dilution 53.4%
- Piotroski F-Score 4/9
No disponible (8)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Eric P. Lefkofsky J.D. | Co-Founder, CEO, President & Chairman | 55 |
| Mr. James Rogers | Chief Financial Officer | 38 |
| Mr. Erik Phelps | Executive VP and Chief Administrative & Legal Officer | 54 |
| Mr. Andrew Polovin | Chief Legal Officer | 51 |
| Mr. Ryan Fukushima | Chief Executive Officer of Data & Apps | 39 |
| Mr. Ryan M. Bartolucci CPA | Chief Accounting Officer | 43 |
| Mr. Shane Colley | Chief Technology Officer | - |
| Dr. Kate A. Sasser Ph.D. | Chief Scientific Officer | 47 |
| Ms. Elizabeth Krutoholow | Vice President of Investor Relations & Competitive Intelligence | - |
| Ms. Christina Antoniou | Senior VP & Head of Corporate Development | - |
Riesgo de Auditoría
1
Riesgo del Consejo
9
Riesgo de Compensación
10
Riesgo de Derechos del Accionista
10
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for TEM, sourced from Markets Gazette.
- 6d agoPOSITIVELe azioni Tempus AI volano grazie a Moderna
Tempus AI (TEM) shares surged on August 19th, fueled by a technical short squeeze triggered by positive third-party clinical trial progress. The stock decisively broke above key moving averages, signaling a bullish trend reversal across multiple timeframes. Following this rally, Tempus AI shares are trading nearly 50% above their July lows. The primary catalyst for TEM's explosive move originated not from Tempus AI itself, but from Phase 3 benchmark results released by Merck and Moderna Inc., which indirectly boosted investor sentiment towards health-tech companies like Tempus AI.
- 5/6/2026POSITIVETempus AI's Big Pharma AI Partnerships Are Getting Bigger And Stickier
Tempus AI reported Q1 revenue of $348.1 million, a substantial 36.1% increase year-over-year, surpassing analyst expectations. The company also raised its 2026 financial outlook, citing robust demand for its artificial intelligence solutions and diagnostic services, particularly within the pharmaceutical sector. These strong results and an optimistic forward-looking statement suggest continued growth and market penetration, which is a positive indicator for investors.
- 3/26/2026POSITIVECathie Wood Chooses Medical AI Over Mark Zuckerberg: Ark Loads Up On TEM Stock, Dumps Meta Shares
Cathie Wood's Ark Invest has significantly increased its exposure to the healthcare technology sector by acquiring shares of Tempus AI (TEM). This strategic move contrasts with a simultaneous reduction in Meta Platforms (META) holdings, indicating a pronounced shift in Ark's investment focus. The decision to favor medical AI specialists like Tempus AI over established big tech giants suggests a strong conviction in the growth potential and disruptive capabilities of AI applications within the healthcare industry. Investors may view this as a signal of strong future performance for companies at the intersection of AI and medicine.
- 2/26/2026POSITIVECathie Wood Is Buying The Tempus AI Dip, Ark Snaps Up Stock Worth $11 Million
Cathie Wood's Ark Invest made a notable move on Wednesday, February 25, 2026, by acquiring $11 million worth of Tempus AI stock. This significant purchase followed a 7% dip in the company's share price. Ark Invest's decision to 'buy the dip' signals strong conviction in Tempus AI's long-term prospects and underlying value, particularly in the wake of a market correction. Investors often view such actions by prominent funds like Ark as a bullish indicator, suggesting that the recent downturn presents an an attractive entry point and reinforcing the potential for future growth in the artificial intelligence sector.
- 2/24/2026NEGATIVETempus AI Stock Drops Despite Q4 Earnings Beat: Details
Tempus AI's stock, TEM, experienced a notable decline despite the company reporting stronger-than-expected Q4 earnings. The healthcare AI firm announced robust financial results, yet investor reaction was unexpectedly negative, leading to a drop in share value. This scenario suggests that the market might have already priced in the positive news, or that there are underlying concerns not immediately apparent in the earnings report, such as cautious future outlooks or a perceived overvaluation. Investors should closely monitor upcoming communications to understand the reasons behind this discrepancy.
via Markets Gazette